REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Sirtuins and Tumor Immunity: Mechanistic Insights, Immunotherapy Prospects, and Therapeutic Horizons
Provisionally accepted
- Second Affiliated Hospital of Jilin University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Sirtuins (SIRTs), a family of NAD⁺-dependent enzymes, exhibit complex and sometimes opposing functions in cancer biology. These enzymes can function as tumor suppressors or promoters, depending on the cellular context, tumor type, and metabolic state. This review provides a mechanistic overview of SIRT isoform regulation of key oncogenic processes, including proliferation, metastasis, metabolic reprogramming, and chemotherapy resistance. Special emphasis is given to their immunomodulatory roles within the tumor microenvironment (TME), where SIRTs influence T cell differentiation, immune checkpoint expression, macrophage polarization, and natural killer cell function. SIRT-driven pathways, such as the nicotinamide phosphoribosyltransferase (NAMPT)–SIRT1–programmed Cell Death Ligand 1 (PD-L1) axis, SIRT6-induced regulatory T cell (Treg) formation, and SIRT2-driven T cell activation, are examined for their effects on immune escape or enhancement and their impact on immunotherapy responses. The review also explores how SIRTs contribute to adaptive mechanisms underlying chemoresistance, including autophagy, epithelial-mesenchymal transition (EMT), redox balance, and mitochondrial protection. The therapeutic landscape of targeting SIRTs is assessed, with discussion of isoform-selective modulators, combination strategies with checkpoint blockade, and challenges in leveraging their context-dependent activities. SIRTs are established as crucial regulators of cancer immunity and therapy, suggesting novel directions for precision oncology. However, given their isoform-and context-dependent duality across tumor types, the clinical translation of SIRT modulators requires careful mechanistic stratification and biomarker-guided patient selection.
Keywords: Sirtuins, Oncogenic processes, Immunotherapy, immune escape, chemoresistance
Received: 06 Sep 2025; Accepted: 18 Nov 2025.
Copyright: © 2025 Wei, Gu, Liu and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qu Wei, quwei@jlu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.